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Introduction
Surgical endarterectomy and endovascular angi-
oplasty represent established treatment modalities 
for stenosis of the internal carotid artery, which is 
responsible for about 20% of cerebral strokes. Now-
adays surgical repair is still regarded as the method 
of choice, while angioplasty and stenting is an alter-
native treatment modality [1–6]. The main problem 
associated with transcutaneous angioplasty is cer-
ebral microembolism during endovascular manoeu-
vres. Although distal protection with filters is pri-
marily used for the protection of cerebral circulation, 
a  proximal protection system, such as the Mo.Ma, 
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A b s t r a c t
Introduction: Although filters are still preferred during carotid stenting, proximal protection systems (PPS) are in-
creasingly used during these procedures. PPS seem to be safer than distal systems, especially in symptomatic pa-
tients, but evidence supporting their use is limited.
Aim: This was a post hoc survey with 30-day mid-term and long-term follow up, which was aimed at assessment of 
the safety and efficacy of stenting of the internal carotid artery under PPS in symptomatic patients.
Material and methods: We analysed the results of stenting in 120 symptomatic patients presenting with at least 
60% stenosis. Patients were aged 67.9 ±9.8 years, and 12 patients were older than 80 years. An occlusion of con-
tralateral artery was found in 5 patients and bilateral stenosis in 26 patients. The primary endpoint of this study was 
the proportion of patients who had new neurological events, including transient ischemic attack and minor or major 
stroke in 30-day follow-up. The secondary endpoint was a composite of technical and clinical success. During long-
term follow-up we assessed new neurological events and stenoses of implanted stents.
Results: The incidence of new neurological events during 30-day follow-up was 0.8%. The rate of technical success 
defined by secondary endpoint was 100%. Mean internal carotid artery stenosis before and after stent implantation 
was 93.8 ±9% and 8.4 ±6.3%, respectively (p < 0.001). Procedural success was achieved in all cases. During long-
term follow-up there were two (1.7%) asymptomatic in-stent stenoses and no (0%) new neurological events.
Conclusions: Endovascular management of symptomatic carotid stenosis under PPS is safe, feasible, and appears to 
be a good alternative to surgical endarterectomy.
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is increasingly used. These systems are character-
ised by a  higher safety profile in comparison with 
distal protection devices [7, 8]. A  proximal protec-
tion system seems to be particularly advantageous 
in symptomatic patients and those older than 
80 years. Research has demonstrated that there are 
fewer microembolic complications after procedures 
performed under proximal protection in comparison 
with carotid stenting with the use of distal protec-
tion devices. In this retrospective study we analysed 
early, mid-, and long-term results of carotid angio-
plasty with stenting under proximal protection in 
symptomatic patients. 
Aim
This post hoc survey, with 30-day mid-term and 
up to 4.5-year long-term follow-up, was aimed at 
assessment of safety and efficacy of stenting pro-
cedure with the use of proximal protection for the 
treatment of internal carotid artery (ICA) stenosis in 
symptomatic patients presenting with at least 60% 
stenosis of this artery. The primary endpoint of this 
study was the proportion of patients who, within 
30 days of carotid intervention, had a new neurologi-
cal event, including transient ischemic attack (TIA) or 
minor or major stroke. The secondary endpoint was 
the mid-term and late composite of technical and 
clinical success. This success was evaluated 24–48 h 
after the procedure, and then at 30-day mid-term 
and late follow-ups, and was defined as a technically 
successful carotid stenting, which was not followed 
by death, stroke, or other cardiovascular event, or by 
a stent occlusion/restenosis. 
Material and methods
We analysed results of the treatment of 120 
consecutive patients (44 women and 76 men) who 
were managed by our team from March 2014 to June 
2018. The mean age of enrolled patients was 67.9 
±9.8 years, and 12 (10%) patients were aged more 
than 80 years. All patients presented with at least 
60% stenosis of the ICA, demonstrated by means of 
colour-coded duplex sonography, computed tomog-
raphy (CT) angiography, or magnetic resonance (MR) 
angiography. Standard preprocedural management 
of the patients comprised multidisciplinary assess-
ment, including neurological, vascular, and cardio-
logic consultations. Potential risks and benefits as-
sociated with the planned procedure were discussed 
with patients, and all of them gave their written, in-
formed consent. The inclusion and exclusion criteria 
are presented in Table I.
All patients analysed in this study were symptom-
atic, which meant that they had an ipsilateral neu-
rological ischaemic event during the 60 days before 
the endovascular procedure. An ischaemic lesion was 
considered ipsilateral if it occurred in the cerebral 
tissue supplied by the target carotid artery. Patients 
were managed at least two days after a neurological 
event, preferentially on the 7th–14th day, depending 
on the findings of CT or MRI of the brain and the ap-
pearance of cerebral lesions revealed by this test. In 
this patient cohort the mean time from neurological 
event to the intervention was 18.7 days. 
In addition to the demographic and clinical data, 
we also analysed angiographic characteristics, such 
as the presence of coexisting lesions in other arter-
ies supplying the brain, including intracranial steno-
ses. Also, we assessed the endovascular technique 
used (type of protection, type of stent, duration of 
the procedure, and duration of the occlusion of the 
artery). Patients’ characteristics and localisation of 
vascular lesions are given in Table II. 
Table I. Inclusion and exclusion criteria
Inclusion criteria:
•	 Symptomatic patient with internal carotid artery stenosis 
≥ 60% as defined by duplex ultrasound, angiography or 
MR angiography
•	 Symptomatic lesions of internal carotid artery is defined 
as a stenosis associated with ipsilateral TIA, amaurosis 
fugax, ischaemic stroke or retinal infarction
•	 Unstable symptomatic lesions of carotid artery, a pres-
ence (or suspect) of thrombi inside the lesion, and 
tortuousness of the target artery
Exclusion criteria:
•	 Rarget lesion that has been previously stented
•	 Highly calcified lesions
•	 Occlusion of the contralateral carotid artery without ade-
quate collateral circulation through the circle of Willis (re-
vealed by means of the transcranial Doppler sonography)
•	 An acute ipsilateral stroke
•	 Other severe pathologies of the brain resulting is signifi-
cant loss of cerebral tissue and/or significant neurologi-
cal deficits
•	 History of haemorrhagic transformation of ischemic 
stroke
•	 Severe co-morbidities (such as cancer or decompensated 
heart failure)
•	 Allergy to aspirin or clopidogrel; to iodinated contrast 
media
•	 A lack of adequate vascular access
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Endovascular procedures were performed by 
a well-trained interventionalist, with an expertise of 
over 1000 endovascular procedures already carried 
out. All procedures were done under local anaesthe-
sia at the vascular access site. Catheter angiography, 
which was performed before and after angioplasty, 
evaluated both ipsi- and contralateral cerebral circu-
lation. Except for 4 patients, who were protected with 
the Gore Flow Reversal System (Gore & Associates, 
Inc., Flagstaff, AZ, USA); in all remaining patients the 
Mo.Ma (Medtronic, Minneapolis, MN, USA) system 
was used.  Stent implantations were performed us-
ing the technique and armamentarium, which were 
tailored to the type and anatomy of the lesion. The 
time of the occlusion of carotid flow by protection 
systems ranged from 2.5 to 15 min (mean: 6.6 ±2.5 
min). Predilatation was performed in 24 out of 120 
stenoses (20%). In 6 patients two stents and in 
1 patient three stents were implanted, primarily be-
cause of a massive protrusion of the plaques through 
the cells of stents. In 91 (75.8%) patients we used 
close-cell stents, including dual-layered stents in 
29 (24.1%) patients. Details regarding protection de-
vices and the stents utilised in this study, and the 
presence of embolic material secured by the protec-
tion systems, are given in Table III.
Table II. Demographic and clinical charac-
teristics of the patients (number of patients:  
N = 120; number of procedures: N = 120)
Patients’ characteristics N Percent
Patients’ age, mean ± SD [years] 67.9 ±9.8
Patients older than 80 year 12 10
Male/female ratio 76/44
Risk factors:
Stable coronary heart disease 25 20.8
Arterial hypertension 108 90.0
Diabetes mellitus type 2 34 28.3
Dislipidemia 80 66.7
Cigarette smoking 29 24.2
Renal impairment 5 4.2
Peripheral artery disease 4 3.3
Chronic obstructive pulmonary 
disease
5 4.2
History of percutaneous coronary 
angioplasty 
13 10.8
History of myocardial infarction 16 13.3
History of transient ischemic 
attack
12 10.0
History of stroke 108 90.0
Bilateral stenosis of the internal 
carotid artery
26 21.7
Occlusion of the internal carotid 
artery
5 4.2
Stenosis of the vertebral artery 9 7.5
Lesion in the left/right internal 
carotid artery
59/61 49.2/50.8
II/III type of the aortic arch 23 19.2
Degree of stenosis, mean ± SD 93.8 ±14.2
Time from neurological event to 
the intervention, mean ± SD [days]
18.7 ±10.2
Localization of stenosis in the 
internal carotid artery:
C1-C2 segment 109 90.8
C3-C4 segment 11 9.2
Table III. Characteristics of protection systems 
and stents utilized in 120 procedures in symp-





Mo.Ma (Medtronic, Minneapolis, 
MN, USA)
116 96.6
Gore Flow Reversal System (Gore & 
Associates, Inc., Flagstaff, AZ, USA) 
4 3.4
Time of occlusions system,  
mean ± SD [min]
6.6 ±2.5
Stents:
Precise (Cordis, Fremont, CA, USA) 29 24.2
Carotid Wallstent (Boston Scientif-
ic, Natick, MA, USA)
49 40.8
Cristallo Ideale (Medtronic, Minne-
apolis, MN, USA)
13 10.8
RoadSaver (Terumo, Tokyo, Japan) 29 24.2
Macroscopically visible embolic ma-
terial in the protection system:
Single plaque or thrombus 31 25.8
A little of debris 3 2.5
A lot of debris 3 2.5
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All patients received aspirin 75 mg/day and 
clopidogrel 75 mg/day. These drugs were adminis-
tered 2–3 days before the planned procedure and 
then for at least 30 days after the intervention 
(typically for 3–6 months). During the procedure 
patients were administered intravenously heparin 
100 units/kg. Periprocedural bradycardias were 
managed with the administration of atropine. Neu-
rological assessment was performed before the 
procedure and on the first or second postprocedural 
day. A sonographic follow-up of the target arteries 
was performed on the first or second postprocedur-
al day, then after 1 and 3 months, and thereafter 
every 6 months. In the case of a neurological event, 
an additional sonographic and neurological assess-
ment was performed. 
Patients were advised to report any neurolog-
ical events that occurred during follow-up. Neu-
rological symptoms were categorised as follows: 
transient ischaemic attack, which was defined as 
an acute neurological deficit resulting from focal 
temporary cerebral or retinal ischaemia that lasted 
less than 24 h; stroke, which was defined as a new 
cerebrovascular event of ischaemic or haemorrhag-
ic aetiology resulting in cerebral infarction and neu-
rological deficit. Strokes were further classified as: 
minor – with neurological deficits lasting less than 
30 days or lasting longer than 30 days, but present-
ing with small deficit (up to 4 points in the Nation-
al Institute of Health Stroke Scale); major – with 
neurological deficits lasting longer than 30 days; 
and fatal – a  stroke (ischaemic or haemorrhagic) 
resulting in death. 
Statistical analysis
Continuous variables were expressed as means 
± standard deviation (SD); categorical variables were 
expressed as percentages. Analysis of normality was 
performed with the Kolmogorov-Smirnov test. Com-
parison of categorical variables between the groups 
was performed using the c2 test. Comparisons of 
continuous variables between the two groups were 
performed using the independent samples t-test. 
Multivariate stepwise backward conditional logistic 
regression analysis was used to determine indepen-
dent predictors of risk of intervention. All significant 
parameters in the univariate analysis were selected 
in the multivariate model. The significance of the 
two-tailed p was set at p < 0.05. Statistical analysis 
was performed using the SPSS software (Statistical 
Package for the Social Sciences (version 25.0 for Ma-
cOS, SPSS Inc., Chicago, IL, USA).
Results
The degree of stenosis of the ICA ranged from 
60% to 99% (mean ± SD: 93.8 ±14.6%), and the 
majority of patients presented with over 70% ste-
nosis. An occlusion of contralateral internal carotid 
artery was found in 5 (4.1%) patients and bilateral 
stenosis in 26 (21.6%) patients. In all cases the en-
dovascular procedure was successful. All patients 
completed the 30-day follow-up. There were nei-
ther fatalities nor major strokes following the inter-
vention in this patient cohort. The mean stenosis 
of internal carotid artery before and after stent im-
plantation was 93.8 ±14.2% and 8.4 ±6.3%, respec-
tively (p < 0.001).
An example of a symptomatic patient with bilat-
eral, critical carotid stenosis qualified for angioplas-
ty with the use of a proximal protection system is 
shown in Photo 1. 
The incidence of new neurological events during 
the 30-day follow-up (the primary endpoint) was 
0.8%. This one ipsilateral minor stroke occurred on 
the fifth postprocedural day in a 62-year-old male, 
who underwent stenting (Carotid WALLSTENT stent) 
of the right ICA under protection with the use of the 
Mo.Ma device. Because the stent was patent, this 
event probably resulted from a  cardiogenic embo-
lism. The rate of technical success defined by the 
secondary endpoint was 100%. 
Five (4.1%) patients developed neurological 
symptoms after introduction of the protection de-
vice, two of them presented with contralateral 
stenoses of the ICA, but there were no clinical con-
sequences related to this intolerance of proximal 
protection. Periprocedurally 8 (6.6%) patients devel-
oped hypotension, which was managed with intra-
venous administration of crystalloids, but it did not 
result in further clinical sequelae. In 2 such patients 
an additional administration of dopamine was need-
ed. Apart from these rather minor events, there were 
no serious periprocedural complications. Logistic 
multivariate analysis revealed some risk factors sig-
nificantly predisposing for the intolerance of a prox-
imal protection device. These comprised patients’ 
age (intolerance of the introduction of protection 
device was more often seen in patients older than 
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80 years, HR = 7.55; p = 0.006), chronic obstructive 
pulmonary disease (HR = 4.305; p = 0.03), and ciga-
rette smoking (HR = 4.012; p = 0.04).
The minimal duration of long-term follow-up was 
5 months, and the mean duration was 594 ±369 
days. In 40 cases it was longer than three years; the 
maximal duration of the follow-up was 4.5 years. 
There were no fatalities during the long-term 
follow-up. Except for the above-described stroke 
that occurred postprocedurally, there were no neu-
rologic adverse events during follow-up. There was 
one non-fatal coronary event requiring percutane-
ous angioplasty. The overall probability of any inci-
dent-free survival was 95.8%, and the probability 
of stroke-free survival was 99.2%. Cumulative prob-
ability of restenosis-free survival in the implanted 
stent was 98.3%, and such a  survival regarding 
coronary events requiring angioplasty was 98.3% 
(Figure 1). Stents in 117 patients were patent and 
without significant stenoses. In 2 patients we 
found an asymptomatic in-stent restenosis. In both 
patients there were no neurological symptoms 
during 8-month follow-up after the re-intervention 
and the stents remained patent. It should be em-
phasised, however, that although the maximum ob-
servation period was over four years, the median 
duration of follow-up was about 2 years; thus, it is 
likely that during a longer follow-up the incidence 
rate of coronary and other non-neurological events 
will be higher.
Discussion
In our material carotid artery stenting with the 
use of proximal protection devices in symptomatic 
patients appeared to be a safe procedure. 
Although carotid stenting is still preferentially 
performed with the use of distal protection, in symp-
tomatic patients a  high rate of ischaemic cerebral 
events after stenting with the use of filters, which 
is some studies was at the level of 10%, cannot be 
ignored [1–4, 9]. By contrast, such adverse events 
associated with stenting under proximal protection 
are less frequent. Open-label studies reported this 
risk at the level of 0.9–2.4% [10–13]. Similarly, there 
were fewer microembolic complications revealed 
by MRI after procedures performed under proximal 
protection in comparison with carotid stenting with 
the use of filters [14–16]. In our study, the Mo.Ma 
system was the preferred proximal protection de-
vice. This system has an established place in the 
armamentarium available for carotid interventions. 
In the non-randomised multicentre study ARMOUR, 
which evaluated a  group of 222 patients and uti-
lized the Mo.Ma system, the composite complica-
tion rate (comprising: stroke, death, and myocardi-
al infarction) was 2.7%, and the stroke rate during 
30 days was 0.9% [12]. In another study the Mo.Ma 
system was used in 1300 patients. The composite 
complication rate (comprising stroke and death) 
at 30-day follow-up was 1.4% (3% in symptomatic 
Photo 1. Patient with bilateral critical internal carotid artery stenosis. A  – Critical, asymptomatic right 
internal carotid artery stenosis. B – Critical, symptomatic left internal carotid artery stenosis. C – Optimal 
angiographic result angioplasty with implantation of a RoadSaver stent in the left carotid internal artery 
with use of proximal protection Mo.Ma 8F (visible balloon of Mo.Ma system in the external carotid artery). 
D – Final optimal angiographic angioplasty of left internal carotid artery - result after removal of the protec-
tion system, with good apposition of the stent in the common and internal left carotid arteries
B C DA
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patients and 0.9% in asymptomatic ones). Of note, 
in this study a  low operator experience (less than 
100 procedures performed) was associated with 
a  higher risk of adverse events [17]. Efficacy and 
safety of an alternative proximal protection system, 
the Gore Flow Reversal System, have been evaluat-
ed in the multicentre prospective, nonrandomised 
study EMPiRE [18]. This study involved 245 patients, 
of whom 30% were symptomatic and 16% were 
older than 80 years. Of note, in this study a contra-
lateral stenosis or occlusion was not the exclusion 
criterion, and actually 10.5% of patients presented 
with such an occlusion. In this study the composite 
complication rate (including stroke, death, myocar-
dial infarction, or TIA) during 30-day follow-up was 
4.5%, while the composite complication rate com-
prising only stroke and death was 2.9% [18]. In an-
other study in which the effectiveness of the Gore 
Flow Reversal System was assessed compared to 
distal protection systems, there were fewer lesions 
in the MRI DWI study, but also a  reduction in the 
number of neurological incidents (comprising stroke, 
death, and myocardial infarction) in the arm using 
the proximal protection system [19]. 
Still, it should be emphasised that the afore-
mentioned trials included both symptomatic and 
asymptomatic patients, and that the percentage of 
symptomatic patients in these studies was not high-
er than 40%. By contrast, in our survey only symp-
tomatic patients were included. Of note, there were 
Figure 1. Kaplan-Meier event-free survival curves for symptomatic patients undergoing carotid artery stent-
ing with proximal protection system. A – Overall survival free from any events. B – Cumulative survival 
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no periprocedural neurological adverse events in 
our patients, while mid-term follow-up has revealed 
a complication rate of 0.8%, which is much less in 
comparison with the other studies. In our opinion, 
such a low complication rate has resulted from the 
fact that in our centre the proximal protection was 
the preferred method for the management of symp-
tomatic patients, even those presenting with critical 
stenosis or contralateral occlusion [20–22]. In con-
trast to the results of the meta-analysis performed 
by Bersin et al. [22], in our study adverse events 
were not more prevalent in patients older than 80 
years, except for more frequent intolerance of the 
protection system. 
However, a  contralateral occlusion or significant 
stenosis represents an important limitation of the 
proximal protection technique. The maximal tolerated 
time of the occlusion of the ICA by a proximal protec-
tion device, according to different authors, should not 
exceed 2.5–15 min [21]. Of note, in our patient series 
5 (4.2%) individuals presented with an occlusion of 
contralateral internal carotid artery, while 25 (20.8%) 
patients had severe bilateral stenosis of the ICAs. 
Neurological symptoms during introduction of the 
system occurred in 5 patients, including two individ-
uals with bilateral stenosis. Nonetheless, there were 
no clinical consequences associated with such intol-
erance. Importantly, all of the aforementioned neuro-
logical symptoms occurred during procedures, which 
were longer than 6–7 min. This further confirms the 
validity of the 5-minute threshold as the safe time of 
endovascular carotid revascularisation [21]. 
The use of closed-cell stents could also account 
for the low stroke rate in our study. Superiority of 
the closed-cell stents in comparison with the open-
cell ones has already been demonstrated in several 
trials [23–25]. In 29 patients we implanted modern 
dual-layered stents (the RoadSaver stents). These 
stents are optimal in cases of severely narrowed 
artery and also in cases of distal (C2-C4 segments 
of the ICA) revascularisation. Good clinical results 
of carotid stenting with the use of such designed 
stents have already been reported [26–28]. Finally, 
an experience of the interventionalists should not 
be ignored [29]. There seems to be a learning curve 
with significant drop in the incidence of adverse 
events after more than 200 procedures performed 
[29, 30]. Other studies have already reported the ex-
pertise of the operator as an independent factor as-
sociated with fewer complications. Besides, closed-
cell stents, which are safer but also more difficult 
to implant, are more willingly used by experienced 
doctors [24].
We are aware of some limitations of this report. 
Firstly, our results are based on the retrospective as-
sessment of data from our registry. Secondly, these 
results were not compared with surgical carotid end-
arterectomy or with endovascular treatments with 
the use of filters. 
Conclusions
In our patient series the endovascular treatment 
of symptomatic carotid stenosis under proximal 
protection was safe and feasible. It appeared to be 
a good alternative to carotid endarterectomy. Low in-
cidence of serious neurological adverse events was 
probably related to extensive operator experience, 
short time of carotid artery occlusion, and tailored 
use of the closed-cell or dual-layered stents.  
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